Activation of MET pathway predicts poor outcome to cetuximab in patients with recurrent or metastatic head and neck cancer
Crossref DOI link: https://doi.org/10.1186/s12967-015-0633-7
Published Online: 2015-08-29
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Madoz-Gúrpide, Juan
Zazo, Sandra
Chamizo, Cristina
Casado, Victoria
Caramés, Cristina
Gavín, Eduardo
Cristóbal, Ion
García-Foncillas, Jesús
Rojo, Federico